179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

Abstract OT1-04-04: EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

10.1158/1538-7445.sabcs19-ot1-04-04 ◽

2020 ◽

Author(s):

Philippe Aftimos ◽

Aditya Bardia ◽

Virginia G Kaklamani ◽

Janice Lu ◽

Teeru Bihani ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Inhibitor Therapy ◽

Advanced Breast ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Abstract OT-01-02: Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2- early breast cancer

10.1158/1538-7445.sabcs20-ot-01-02 ◽

2021 ◽

Author(s):

Oleg Gluz ◽

Tom Degenhardt ◽

Norbert Marschner ◽

Matthias Christgen ◽

Hans Heinrich Kreipe ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Open Label ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

10.1158/1538-7445.sabcs17-ot3-05-07 ◽

2018 ◽

Cited By ~ 1

Author(s):

O Metzger-Filho ◽

S Mandrekar ◽

S Loibl ◽

E Ciruelos ◽

L Gianni ◽

...

Keyword(s):

Endocrine Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.357 ◽

2018 ◽

Vol 29 ◽

pp. viii121 ◽

Cited By ~ 1

Author(s):

S. Loibl ◽

O. Metzger ◽

S.J. Mandrekar ◽

C. Mundhenke ◽

S. Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs18-ot3-02-07 ◽

2019 ◽

Author(s):

O Metzger ◽

S Mandrekar ◽

S Loibl ◽

C Mundhenke ◽

S Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdx365.087 ◽

2017 ◽

Vol 28 ◽

pp. v107-v108

Author(s):

O. Metzger ◽

S. Mandrekar ◽

E. Ciruelos ◽

S. Loibl ◽

P. Valagussa ◽

...

Keyword(s):

Endocrine Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy097 ◽

2018 ◽

Vol 48 (9) ◽

pp. 855-859 ◽

Cited By ~ 2

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Naruto Taira ◽

Masahiro Kashiwaba ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Previously Treated

Efficacy and Safety of Carboplatin With Nab-Paclitaxel Versus Docetaxel in Elderly Patients with Squamous-Cell Lung Cancer (CAPITAL): A Randomized, Multicenter, Open-Label, Phase III Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3847741 ◽

2021 ◽

Author(s):

Yoshihito Kogure ◽

Shunichiro Iwasawa ◽

Hideo Saka ◽

Yoichiro Hamamoto ◽

Akiko Kada ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Phase Iii ◽

Squamous Cell Lung Cancer ◽

Efficacy And Safety ◽

Open Label ◽

Phase Iii Trial ◽

Postoperative Adjuvant Anastrozole for 10 Rather than 5 Years in Patients with Oestrogen Receptor-Positive Breast Cancer: AERAS, a Randomised Multicentre Open-Label Phase III Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3918274 ◽

2021 ◽

Author(s):

Takuji Iwase ◽

Shigehira Saji ◽

Kotaro Iijima ◽

Kenji Higaki ◽

Shoichiro Ohtani ◽

...

Keyword(s):

Breast Cancer ◽

Oestrogen Receptor ◽

Phase Iii ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Positive Breast Cancer

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250mg With Fulvestrant 500mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2012.04.003 ◽

2012 ◽

Vol 23 (2) ◽

pp. 190-191

Author(s):

V.C. Jordan

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Estrogen Receptor Positive